| Literature DB >> 28109182 |
Lin Han1,2, Yuxia Ma2,3, Suhong Wei4, Jinhui Tian5, Xiaochun Yang6, Xiping Shen7, Jun Zhang8, Yuexian Shi9.
Abstract
AIMS/Entities:
Keywords: Diabetes; Home visit; Meta-analysis
Mesh:
Substances:
Year: 2017 PMID: 28109182 PMCID: PMC5583953 DOI: 10.1111/jdi.12630
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Figure 1Flowchart of literature search. RCT, randomized controlled trial.
Characteristics of the included randomized controlled trials
| Study | Study location | Type of study | Setting | Sample size ( | Sex (Female/Male) | Mean age range, years (SD) | Program duration (frequency) | Intervention group | Control group | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Home visit | Usual care | Home visit | Usual care | Home visit | Usual care | |||||||
| Couper (1999) | Australia | RCT | Home | 37 | 32 | 19/18 | 22/10 | 14.2 (1.7) | 14.3 (1.9) | 6 months (monthly) | Home visit | Usual care |
| Estey (2015) | Canada | RCT | Home | 28 | 25 | 11/17 | 11/14 | _ | _ | 3 months (2 weeks) | Home visit | Usual care |
| Rothschild (2014) | USA | RCT | Home | 73 | 71 | 47/26 | 50/21 | 53.76 (11.7) | 53.66 (12.7) | 2 years (20 days) | Home visit | Usual care |
| Spencer (2011) | USA | RCT | Home | 59 | 77 | 54/18 | 62/30 | 50 (5) | 55 (4) | 6 months (2 weeks) | Home visit | Usual care |
| Stroup (2003) | USA | RCT | Home | 30 | 40 | 20/10 | 17/23 | 58.6 (8.6) | 52.1 (21.2) | 2 years (monthly) | Home visit | Usual care |
| Taylor (2005) | USA | RCT | Home | 20 | 19 | 7/13 | 6/13 | 58 | 67 | 3 months (2 weeks) | Home visit | Usual care |
| Wattana (2007) | Thailand | RCT | Home | 75 | 72 | 60/15 | 52/20 | 58.40 (10.05) | 55.14 (10.22) | 24 weeks (–) | Home visit | Usual care |
RCT, randomized controlled trial; SD, standard deviation.
Figure 2Risk of bias in the included studies.
Figure 3Change in glycated hemoglobin with home visits compared with usual care. WMD, weighted mean difference.
Summary of meta‐analyses of studies using home visits to manage diabetes
| Outcome measure | Trails | Sample size (intervention/control) | Measure of effects | Intervention effect size (95% CI) |
| Heterogeneity | |
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| SBP (mmHg) | 2 | 109 (59/50) | MD | −5.94 (−11.34, −0.54) | 0.03 | 0 | 0.001 |
| DBP (mmHg) | 2 | 109 (59/50) | MD | −6.32 (−12.00, −0.65) | 0.03 | 48 | 0.001 |
| Quality of life | 2 | 186 (95/91) | SMD | 11.81 (7.20, 16.42) | 0.001 | 23 | 0.25 |
| High density lipoprotein (mg/dL) | 2 | 109 (50/59) | MD | −5.11 (−9.80, −0.43) | 0.03 | 0 | 0.4 |
| Low density lipoprotein (mg/dL) | 2 | 109 (50/59) | MD | −10.12 (−18.23, −2.00) | 0.01 | 0 | 0.75 |
| Weight (kg) | 2 | 123 (58/65) | MD | −5.06 (−12.61, 2.48) | 0.19 | 16 | 0.28 |
| Total cholesterol (mg/dL) | 2 | 109 (50/59) | MD | −4.06 (−18.28, 10.17) | 0.58 | 0 | 0.93 |
| Total triglycerides (mg/dL) | 2 | 109 (50/59) | MD | 50.72 (15.69, 85.75) | 0.005 | 0 | 0.51 |
| Body mass index (kg/m2) | 1 | 164 (72/92) | MD | 1 (−0.13, 2.13) | 0.08 | NA | NA |
| Self‐efficacy | 1 | 120 (56/74) | MD | −1.80 (−5.37, 1.77) | 0.32 | NA | NA |
| Self‐management | 1 | 120 (56/74) | MD | 0.70 (0.51, 0.89) | 0.001 | NA | NA |
*P < 0.05, **P < 0.01. Heterogeneity (I 2): <50% = low, 50–75% = moderate, >75% = high. CI, confidence intervals; MD, mean difference; NA, not applicable; SMD, standardized mean difference.
Figure 4Funnel plot of the meta‐analysis. SE, standard error; WMD, weighted mean difference.